{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:54:38Z","timestamp":1761746078448,"version":"3.40.4"},"reference-count":95,"publisher":"The Japan Society of Coloproctology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Anus Rectum Colon"],"published-print":{"date-parts":[[2025,4,25]]},"DOI":"10.23922\/jarc.2025-001","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T22:09:09Z","timestamp":1745532549000},"page":"167-178","source":"Crossref","is-referenced-by-count":1,"title":["Hereditary Colorectal Cancer: Clinical Implications of Genomic Medicine and Precision Oncology"],"prefix":"10.23922","volume":"9","author":[{"given":"Atsushi","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital"},{"name":"Department of Real-World Data Research and Development, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10009","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017 Apr; 35 (10): 1086-95.","DOI":"10.1200\/JCO.2016.71.0012"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pearlman R, Frankel WL, Swanson BJ, et al. Prospective statewide study of universal screening for hereditary colorectal cancer: the Ohio Colorectal Cancer Prevention Initiative. JCO Precis Oncol. 2021 May; 5: PO.20.00525.","DOI":"10.1200\/PO.20.00525"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. J\u00e4rvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000 May; 118 (5): 829-34.","DOI":"10.1016\/S0016-5085(00)70168-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sepp\u00e4l\u00e4 TT, Latchford A, Negoi I, et al. European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. Br J Surg. 2021 May; 108 (5): 484-98.","DOI":"10.1002\/bjs.11902"},{"key":"5","unstructured":"5. Crosbie EJ, Ryan NAJ, Arends MJ, et al. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med. 2019 Oct; 21 (10): 2390-400."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yoshino T, Cervantes A, Bando H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 2023 Jun; 8 (3): 101558.","DOI":"10.1016\/j.esmoop.2023.101558"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kuzbari Z, Bandlamudi C, Loveday C, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023 Mar; 34 (3): 215-27.","DOI":"10.1016\/j.annonc.2022.12.003"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cragun D, Radford C, Dolinsky JS, et al. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet. 2014 Dec; 86 (6): 510-20.","DOI":"10.1111\/cge.12359"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yurgelun MB, Allen B, Kaldate RR, et al. Identification of a variety of mutations in cancer-predisposition genes in patients with suspected Lynch syndrome. Gastroenterology. 2015 Sep; 149 (3): 604-13.","DOI":"10.1053\/j.gastro.2015.05.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Esplin ED, Nielsen SM, Bristow SL, et al. Universal germline genetic testing for hereditary cancer syndromes in patients with solid tumor cancer. JCO Precis Oncol. 2022 Sep; 6: e2100516.","DOI":"10.1200\/PO.21.00516"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Shen Y, Chen W, Fu C, et al. Polygenic risk score, healthy lifestyle score, and colorectal cancer risk: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2024 Nov; doi: 10.1158\/1055-9965.EPI-24-1013. Online ahead of print.","DOI":"10.1158\/1055-9965.EPI-24-1013"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pearlman R, Frankel WL, Swanson B, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017 Apr; 3 (4): 464-71.","DOI":"10.1001\/jamaoncol.2016.5194"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Stoffel EM, Koeppe E, Everett J, et al. Germline genetic features of young individuals with colorectal cancer. Gastroenterology. 2018 Mar; 154 (4): 897-905.","DOI":"10.1053\/j.gastro.2017.11.004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Stanich PP, Pelstring KR, Hampel H, et al. A high percentage of early-age onset colorectal cancer is potentially preventable. Gastroenterology. 2021 Apr; 160 (5): 1850-2.","DOI":"10.1053\/j.gastro.2020.12.009"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Coughlin SE, Heald B, Clark DF, et al. Multigene panel testing yields high rates of clinically actionable variants among patients with colorectal cancer. JCO Precis Oncol. 2022 Nov; 6: e2200517.","DOI":"10.1200\/PO.22.00517"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Valle L, Vilar E, Tavtigian SV, et al. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol. 2019 Apr; 247 (5): 574-88.","DOI":"10.1002\/path.5229"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rosenblum RE, Ang C, Suckiel SA, et al. Lynch syndrome-associated variants and cancer rates in an ancestrally diverse biobank. JCO Precis Oncol. 2020 Nov; 4: PO.20.00290.","DOI":"10.1200\/PO.20.00290"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fummey E, Navarro P, Plazzer JP, et al. Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank. J Med Genet. 2024 Aug; 61 (9): 861-9.","DOI":"10.1136\/jmg-2023-109791"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009 Jul; 76 (1): 1-18.","DOI":"10.1111\/j.1399-0004.2009.01230.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tomita N, Ishida H, Tanakaya K, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the clinical practice of hereditary colorectal cancer. Int J Clin Oncol. 2021 Aug; 26 (8): 1353-419.","DOI":"10.1007\/s10147-021-01881-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999 Jun; 116 (6): 1453-6.","DOI":"10.1016\/S0016-5085(99)70510-X"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 Feb; 96 (4): 261-8.","DOI":"10.1093\/jnci\/djh034"},{"key":"23","unstructured":"23. Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol. 2019 Feb; 37 (4): 286-95."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yamada A, Doi Y, Minamiguchi S, et al. Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers. Int J Clin Oncol. 2024 Nov; 29 (11): 1696-703.","DOI":"10.1007\/s10147-024-02609-w"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yamada A, Matsuoka Y, Minamiguchi S, et al. Real-world outcome of universal screening for Lynch syndrome in Japanese patients with colorectal cancer highlights the importance of targeting patients with young-onset disease. Mol Clin Oncol. 2021 Dec; 15 (6): 247.","DOI":"10.3892\/mco.2021.2409"},{"key":"26","unstructured":"26. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun; 372 (26): 2509-20."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Harrold EC, Foote MB, Rousseau B, et al. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade. Nat Med. 2023 Oct; 29 (10): 2458-63.","DOI":"10.1038\/s41591-023-02544-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet. 2009 Dec; 46 (12): 793-802.","DOI":"10.1136\/jmg.2009.068122"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Hitchins MP, D\u00e1maso E, Alvarez R, et al. Constitutional MLH1 methylation is a major contributor to mismatch repair-deficient, MLH1-methylated colorectal cancer in patients aged 55 years and younger. J Natl Compr Canc Netw. 2023 Jul; 21 (7): 743-52.","DOI":"10.6004\/jnccn.2023.7020"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Castillejo A, Hern\u00e1ndez-Ill\u00e1n E, Rodriguez-Soler M, et al. Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer. J Med Genet. 2015 Jul; 52 (7): 498-502.","DOI":"10.1136\/jmedgenet-2015-103076"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Colas C, Guerrini-Rousseau L, Suerink M, et al. ERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counselling, surveillance, quality of life, and clinical management. Eur J Hum Genet. 2024 Dec; 32 (12): 1526-41.","DOI":"10.1038\/s41431-024-01708-6"},{"key":"32","unstructured":"32. Ercan AB, Aronson M, Fernandez NR, et al. Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study. Lancet Oncol. 2024 May; 25 (5): 668-82."},{"key":"33","unstructured":"33. Durno C, Ercan AB, Bianchi V, et al. Survival benefit for individuals with constitutional mismatch repair deficiency undergoing surveillance. J Clin Oncol. 2021 Sep; 39 (25): 2779-90."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005 Apr; 293 (16): 1979-85.","DOI":"10.1001\/jama.293.16.1979"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Dominguez-Valentin M, Therkildsen C, Da Silva S, et al. Familial colorectal cancer type X: genetic profiles and phenotypic features. Mod Pathol. 2015 Jan; 28 (1): 30-6.","DOI":"10.1038\/modpathol.2014.49"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Yamaguchi T, Furukawa Y, Nakamura Y, et al. Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Jpn J Clin Oncol. 2015 Feb; 45 (2): 153-9.","DOI":"10.1093\/jjco\/hyu190"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Bucksch K, Zachariae S, Aretz S, et al. Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study. BMC Cancer. 2020 May; 20 (1): 460.","DOI":"10.1186\/s12885-020-06926-x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Choi YH, Lakhal-Chaieb L, Kr\u00f6l A, et al. Risks of colorectal cancer and cancer-related mortality in familial colorectal cancer type X and Lynch syndrome families. J Natl Cancer Inst. 2019 Jul; 111 (7): 675-83.","DOI":"10.1093\/jnci\/djy159"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Bucksch K, Zachariae S, Ahadova A, et al. Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X. Int J Cancer. 2022 Jan; 150 (1): 56-66.","DOI":"10.1002\/ijc.33790"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Hatfield E, Green JS, Woods MO, et al. Impact of colonoscopic screening in Familial Colorectal Cancer Type X. Mol Genet Genomic Med. 2018 Nov; 6 (6): 1021-30.","DOI":"10.1002\/mgg3.478"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Garre P, Mart\u00edn L, Sanz J, et al. BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X. Clin Genet. 2015 Jun; 87 (6): 582-7.","DOI":"10.1111\/cge.12427"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Nieminen TT, Abdel-Rahman WM, Ristim\u00e4ki A, et al. BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology. 2011 Jul; 141 (1): e23-6.","DOI":"10.1053\/j.gastro.2011.03.063"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Segu\u00ed N, Mina LB, L\u00e1zaro C, et al. Germline mutations in FAN1 cause hereditary colorectal cancer by impairing DNA repair. Gastroenterology. 2015 Sep; 149 (3): 563-6.","DOI":"10.1053\/j.gastro.2015.05.056"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Garre P, Brice\u00f1o V, Xicola RM, et al. Analysis of the oxidative damage repair genes NUDT1, OGG1, and MUTYH in patients from mismatch repair proficient HNPCC families (MSS-HNPCC). Clin Cancer Res. 2011 Apr; 17 (7): 1701-12.","DOI":"10.1158\/1078-0432.CCR-10-2491"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Nieminen TT, O'Donohue MF, Wu Y, et al. Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency. Gastroenterology. 2014 Sep; 147 (3): 595-8.","DOI":"10.1053\/j.gastro.2014.06.009"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Schulz E, Klampfl P, Holzapfel S, et al. Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nat Commun. 2014 Oct; 5: 5191.","DOI":"10.1038\/ncomms6191"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Mart\u00edn-Morales L, Feldman M, Vershinin Z, et al. SETD6 dominant negative mutation in familial colorectal cancer type X. Hum Mol Genet. 2017 Nov; 26 (22): 4481-93.","DOI":"10.1093\/hmg\/ddx336"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Chan JM, Clendenning M, Joseland S, et al. Inherited BRCA1 and RNF43 pathogenic variants in a familial colorectal cancer type X family. Fam Cancer. 2024 Mar; 23 (1): 9-21.","DOI":"10.1007\/s10689-023-00351-2"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Vasen HF, M\u00f6slein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008 May; 57 (5): 704-13.","DOI":"10.1136\/gut.2007.136127"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Zaffaroni G, Mannucci A, Koskenvuo L, et al. Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision. Br J Surg. 2024 May; 111 (5): znae070.","DOI":"10.1093\/bjs\/znae070"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012 Aug; 308 (5): 485-92.","DOI":"10.1001\/jama.2012.8780"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Takao M, Yamaguchi T, Eguchi H, et al. APC germline variant analysis in the adenomatous polyposis phenotype in Japanese patients. Int J Clin Oncol. 2021 Sep; 26 (9): 1661-70.","DOI":"10.1007\/s10147-021-01946-4"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Nielsen M, Hes FJ, Nagengast FM, et al. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet. 2007 May; 71 (5): 427-33.","DOI":"10.1111\/j.1399-0004.2007.00766.x"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Macrae F, du Sart D, Nasioulas S. Familial adenomatous polyposis. Best Pract Res Clin Gastroenterol. 2009; 23 (2): 197-207.","DOI":"10.1016\/j.bpg.2009.02.010"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Kim B, Won D, Jang M, et al. Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic APC gene mutation detection in patients with familial adenomatous polyposis. BMC Med Genomics. 2019 Jul; 12 (1): 103.","DOI":"10.1186\/s12920-019-0553-0"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Young CC, Horton C, Grzybowski J, et al. Solving missing heritability in patients with familial adenomatous polyposis with DNA-RNA paired testing. JCO Precis Oncol. 2024 Mar; 8: e2300404.","DOI":"10.1200\/PO.23.00404"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Weren RD, Ligtenberg MJ, Geurts van Kessel A, et al. NTHL1 and MUTYH polyposis syndromes: two sides of the same coin? J Pathol. 2018 Feb; 244 (2): 135-42.","DOI":"10.1002\/path.5002"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Magrin L, Fanale D, Brando C, et al. MUTYH-associated tumor syndrome: the other face of MAP. Oncogene. 2022 Apr; 41 (18): 2531-9.","DOI":"10.1038\/s41388-022-02304-y"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Boparai KS, Dekker E, Van Eeden S, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology. 2008 Dec; 135 (6): 2014-8.","DOI":"10.1053\/j.gastro.2008.09.020"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Viel A, Bruselles A, Meccia E, et al. A specific mutational signature associated with DNA 8-oxoguanine persistence in MUTYH-defective colorectal cancer. EBioMedicine. 2017 Jun; 20: 39-49.","DOI":"10.1016\/j.ebiom.2017.04.022"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Rivera B, Castellsagu\u00e9 E, Bah I, et al. Biallelic NTHL1 mutations in a woman with multiple primary tumors. N Engl J Med. 2015 Nov; 373 (20): 1985-6.","DOI":"10.1056\/NEJMc1506878"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Weren RD, Ligtenberg MJ, Kets CM, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet. 2015 Jun; 47 (6): 668-71.","DOI":"10.1038\/ng.3287"},{"key":"63","unstructured":"63. Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013 Feb; 45 (2): 136-44."},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Palles C, Martin L, Domingo E, et al. The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management. Fam Cancer. 2022 Apr; 21 (2): 197-209.","DOI":"10.1007\/s10689-021-00256-y"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Jul; 487 (7407): 330-7.","DOI":"10.1038\/nature11252"},{"key":"66","unstructured":"66. Ambrosini M, Rousseau B, Manca P, et al. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul; 35 (7): 643-55."},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct; 21 (10): 1353-65.","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Chan JM, Clendenning M, Joseland S, et al. Rare germline variants in the AXIN2 gene in families with colonic polyposis and colorectal cancer. Fam Cancer. 2022 Oct; 21 (4): 399-413.","DOI":"10.1007\/s10689-021-00283-9"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Leclerc J, Beaumont M, Vibert R, et al. AXIN2 germline testing in a French cohort validates pathogenic variants as a rare cause of predisposition to colorectal polyposis and cancer. Genes Chromosomes Cancer. 2023 Apr; 62 (4): 210-22.","DOI":"10.1002\/gcc.23112"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Tanakaya K, Kumamoto K, Tada Y, et al. A germline MBD4 mutation was identified in a patient with colorectal oligopolyposis and early-onset cancer: A case report. Oncol Rep. 2019 Sep; 42 (3): 1133-40.","DOI":"10.3892\/or.2019.7239"},{"key":"71","unstructured":"71. Palles C, West HD, Chew E, et al. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. Am J Hum Genet. 2022 May; 109 (5): 953-60."},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Adam R, Spier I, Zhao B, et al. Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet. 2016 Aug; 99 (2): 337-51.","DOI":"10.1016\/j.ajhg.2016.06.015"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Olkinuora A, Nieminen TT, M\u00e5rtensson E, et al. Biallelic germline nonsense variant of MLH3 underlies polyposis predisposition. Genet Med. 2019 Aug; 21 (8): 1868-73.","DOI":"10.1038\/s41436-018-0405-x"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Stanich PP, Pearlman R, Hinton A, et al. Prevalence of germline mutations in polyposis and colorectal cancer-associated genes in patients with multiple colorectal polyps. Clin Gastroenterol Hepatol. 2019 Sep; 17 (10): 2008-15.","DOI":"10.1016\/j.cgh.2018.12.008"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Lorans M, Dow E, Macrae FA, et al. Update on hereditary colorectal cancer: improving the clinical utility of multigene panel testing. Clin Colorectal Cancer. 2018 Jun; 17 (2): e293-305.","DOI":"10.1016\/j.clcc.2018.01.001"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Dal Buono A, Gaiani F, Poliani L, et al. Juvenile polyposis syndrome: an overview. Best Pract Res Clin Gastroenterol. 2022 Jun-Aug; 58-59: 101799.","DOI":"10.1016\/j.bpg.2022.101799"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Matsumoto T, Umeno J, Jimbo K, et al. Clinical guidelines for diagnosis and management of juvenile polyposis syndrome in children and adults-secondary publication. J Anus Rectum Colon. 2023 Apr; 7 (2): 115-25.","DOI":"10.23922\/jarc.2023-002"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Wagner A, Aretz S, Auranen A, et al. The management of Peutz-Jeghers syndrome: European hereditary tumour group (EHTG) guideline. J Clin Med. 2021 Jan; 10 (3): 473.","DOI":"10.3390\/jcm10030473"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Yamamoto H, Sakamoto H, Kumagai H, et al. Clinical guidelines for diagnosis and management of Peutz-Jeghers syndrome in children and adults. Digestion. 2023; 104 (5): 335-47.","DOI":"10.1159\/000529799"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013 Nov; 105 (21): 1607-16.","DOI":"10.1093\/jnci\/djt277"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Takayama T, Muguruma N, Igarashi M, et al. Clinical guidelines for diagnosis and management of Cowden syndrome\/PTEN hamartoma tumor syndrome in children and adults-secondary publication. J Anus Rectum Colon. 2023 Oct; 7 (4): 284-300.","DOI":"10.23922\/jarc.2023-028"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Liu S, Ma Y, You W, et al. Hamartomatous polyposis syndrome associated malignancies: risk, pathogenesis and endoscopic surveillance. J Dig Dis. 2021 Aug; 22 (8): 444-51.","DOI":"10.1111\/1751-2980.13029"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Carballal S, Balaguer F, IJspeert JEG. Serrated polyposis syndrome; epidemiology and management. Best Pract Res Clin Gastroenterol. 2022 Jun-Aug; 58-59: 101791.","DOI":"10.1016\/j.bpg.2022.101791"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Shimohara Y, Urabe Y, Oka S, et al. Clinicopathological characteristics of colorectal serrated polyposis syndrome (SPS): results of a multicenter study by the SPS Study Group in Japan. J Gastroenterol. 2022 Apr; 57 (4): 300-8.","DOI":"10.1007\/s00535-022-01859-7"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Gala MK, Mizukami Y, Le LP, et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology. 2014 Feb; 146 (2): 520-9.","DOI":"10.1053\/j.gastro.2013.10.045"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Murphy A, Solomons J, Risby P, et al. Germline variant testing in serrated polyposis syndrome. J Gastroenterol Hepatol. 2022 May; 37 (5): 861-9.","DOI":"10.1111\/jgh.15791"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Li MM, Chao E, Esplin ED, et al. Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020 Jul; 22 (7): 1142-8.","DOI":"10.1038\/s41436-020-0783-8"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Liu YL, Stadler ZK. The future of parallel tumor and germline genetic testing: is there a role for all patients with cancer? J Natl Compr Canc Netw. 2021 Jul; 19 (7): 871-8.","DOI":"10.6004\/jnccn.2021.7044"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017 Apr; 17 (4): 223-38.","DOI":"10.1038\/nrc.2017.7"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Kondo T, Yamamoto Y, Fukuyama K, et al. Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling. Int J Clin Oncol. 2022 Aug; 27 (8): 1256-63.","DOI":"10.1007\/s10147-022-02176-y"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Cavestro GM, Mannucci A, Balaguer F, et al. Delphi initiative for early-onset colorectal cancer (DIRECt) international management guidelines. Clin Gastroenterol Hepatol. 2023 Mar; 21 (3): 581-603.","DOI":"10.1016\/j.cgh.2022.12.020"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. O'Sullivan DE, Sutherland RL, Town S, et al. Risk factors for early-onset colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022 Jun; 20 (6): 1229-40.","DOI":"10.1016\/j.cgh.2021.01.037"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Whitworth PW, Beitsch PD, Patel R, et al. Clinical utility of universal germline genetic testing for patients with breast cancer. JAMA Netw Open. 2022 Sep; 5 (9): e2232787.","DOI":"10.1001\/jamanetworkopen.2022.32787"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Bj\u00f8rnstad PM, Aal\u00f8kken R, \u00c5sheim J, et al. A 39 kb structural variant causing Lynch Syndrome detected by optical genome mapping and nanopore sequencing. Eur J Hum Genet. 2024 May; 32 (5): 513-20.","DOI":"10.1038\/s41431-023-01494-7"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Nakamura W, Hirata M, Oda S, et al. Assessing the efficacy of target adaptive sampling long-read sequencing through hereditary cancer patient genomes. NPJ Genom Med. 2024 Feb; 9 (1): 11.","DOI":"10.1101\/2023.05.30.23289318"}],"container-title":["Journal of the Anus, Rectum and Colon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/9\/2\/9_2025-001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:36:35Z","timestamp":1745642195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/9\/2\/9_2025-001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.23922\/jarc.2025-001","relation":{},"ISSN":["2432-3853"],"issn-type":[{"type":"electronic","value":"2432-3853"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"2025-001"}}